Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131390) titled 'Efficacy and Safety of MRG003 in Combination with Putolimab as Neoadjuvant Therapy for Locally Advanced Oropharyngeal Squamous Cell Carcinoma: A Phase II, Single-Arm, Multicenter Clinical Study' on Sept. 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-sen University Cancer Center
Condition:
Locally advanced oropharyngeal squamous cell carcinoma (OPSCC)
Intervention:
HPV-positive OPSCC group:MRG003 at 2.0 mg/kg via intravenous infusion every 3 weeks, plus pertuzumab at 200 mg via intravenous infusion every 3 weeks
2 courses.
HPV-negative OPSCC group:MRG003 at 2.0 mg/kg...